Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neratinib in HER2+ Breast Cancer with Brain Metastases
NCT04856475Phase 2Withdrawn
- Sponsor
- Institut Jules Bordet
- Start
- Nov 2021
- Primary completion
- Nov 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of neratinib in HER2-positive breast cancer, brain metastasis (BM), leptomeningeal carcinomatosis (LMC), sponsored by Institut Jules Bordet. Planned start Nov 2021; status: withdrawn.
02
Drugs
neratinib
03
Conditions
HER2-positive breast cancerbrain metastasis (BM)leptomeningeal carcinomatosis (LMC)
Beyond the preview
Go deeper on NCT04856475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856475.